Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
URMC / Eastman Institute for Oral Health / Word of Mouth / November 2019 / Dr. Sharon Elad Recognized for Leadership

Dr. Sharon Elad Recognized for Leadership

The Multinational Association of Supportive Care in Cancer presented two new awards to recognize outstanding work by a MASCC Study Group and an Outstanding Study Group Leader.

Dr. Sharon EladSharon Elad, DMD, MSc, professor and chair, Oral Medicine at Eastman Institute for Oral Health, was awarded the 2019 Outstanding Study Group Leader, and the Mucositis Study Group she chaired was named the 2019 Outstanding Study Group. 

Projects carried out by Study Groups result in clinical practice guidelines, position papers, publications, and other products that advance supportive care in cancer.

Sharon has published widely and is recognized as an international expert on oral complications of cancer treatment, such as mucositis, osteonecrosis of the jaw, and chronic graft-versus-host disease, as well as dental management of these patients. Previously, she chaired the Israeli Society of Oral Medicine (2002-2010) and served as General Secretary for the International Society of Oral Oncology (ISOO) (2005-2013). Sharon Elad is among the select few who have received the Honorary Diplomate Award from the American Board of Oral Medicine.

In 2009, Dr. Elad was elected to serve as co-chair of the MSG and, since 2015, has served as chair. She has taken a leading role in the development and publication of several guidelines and position papers. She has participated in all the MASCC/ISOO Mucositis Guidelines updates and attended the respective Guidelines Meetings including those in Geneva (2005), Athens (2011), and Washington, DC (2017).

The Mucositis Study Group
The Mucositis Study Group's goal is to improve outcomes of patients experiencing oral and gastrointestinal mucositis associated with anticancer therapies. The MSG currently includes 245 members from 33 countries. Dr. Elad is assisted by vice-chairs Paolo Bossi, MD, and Karis Kin Fong Cheng, PhD, RN.

The MSG has developed the MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis, originally published in 2004, and updated in 2007, 2014, and earlier this year in Supportive Care in Cancer. These guidelines have been endorsed or referenced by several major professional societies in oncology, including the Oncology Nursing Society, the European Society of Medical Oncology, and the National Comprehensive Cancer Network.

The MSG regularly organizes educational sessions on mucositis at MASCC/ISOO Annual Meetings. These sessions include both basic science research and clinical topics. MSG parallel sessions, as well as Mucositis Research Workshops, allow a stage for investigators to present cutting-edge research. These sessions include expert presentations and interaction among participants from all over the world. In particular, these workshops provide practical information related to the clinical management of mucositis and useful information for conducting research.  The most recent Workshop in San Francisco focused on mucositis-associated pain and new insights about the pathogenesis of mucositis. It brought together basic, translational, and clinical researchers in an exciting and interactive setting to advance the understanding of mucositis mechanisms and management.

The MSG developed free, patient-friendly versions of the evidence-based Clinical Practice Guidelines for the Management of Oral Mucositis. These materials, available on the MASCC website, include mucositis management for patients treated with chemotherapy, patients undergoing hematopoietic stem cell transplantation, and patients treated with radiotherapy involving the head and neck.

Reprinted  in part with permission from the Multinational Association of Supportive Care in Cancer.


Karen Black | 11/6/2019

You may also like